阿帕替尼联合金龙胶囊治疗中晚期肝癌的临床疗效研究

Clinical Efficacy of Apatinib Combined with Jinlong Capsule in The Treatment of Advanced Liver Cancer

目的:分析甲磺酸阿帕替尼联合金龙胶囊治疗中晚期原发性肝癌的临床疗效及安全性。方法:将30例中晚期原发性肝癌患者按随机数字表法分为观察组、对照组,每组15例。2组均为中晚期肝癌的患者,观察组采用阿帕替尼联合金龙胶囊治疗,对照组采用阿帕替尼治疗随访观察。观察2组患者治疗3月后、6月、1年后随访患者病情变化(饮食、疼痛、腹胀等情况)及复查甲胎蛋白(alpha fetoprotein, AFP)、影像学检查(腹水、肿瘤大小)等的变化。结果:观察组AFP、影像学测量肿瘤变化、腹水均较对照组改善,近期生活质量及不良反应发生较对照组好(P<0.05)。实验组缓解率以及生存周期均得到延长(P<0.05)。结论:通过对中晚期原发性肝癌患者进行甲磺酸阿帕替尼联合金龙胶囊治疗后,临床治疗效果明显,安全性高。

Objective:To analyze the clinical efficacy and safety of apatinib mesylate combined with Jinlong capsule in the treatment of advanced primary liver cancer.Methods:Thirty patients with advanced primary liver cancer were divided into observation group and control group according to random number table,15 cases in each group.Both groups were patients with advanced liver cancer.The observation group was treated with apatinib combined with Jinlong capsule,and the control group was treated with apatinib for follow-up observation.The changes of the patients’condition(diet,pain,bloating,etc.)and the review of alpha-fetoprotein(AFP)and imaging examination(ascites,tumor size)were observed after 3 months,June,and 1 year.Results:The alpha fetoprotein(AFP),imaging changes,and ascites were better in the observation group than in the control group.The quality of life and adverse reactions in the observation group were better than those in the control group(P<0.05).The remission rate and survival cycle of the experimental group were prolonged(P<0.05).Conclusion:After the treatment of patients with advanced hepatocellular carcinoma with apatinib mesylate and Jinlong capsule,the clinical treatment effect is obvious and the safety is high.